Articles On MGC Pharmaceuticals (ASX:MXC)

MGC Pharmaceuticals Ltd (ASX: MXC) is one to watch this afternoon. The MGC Pharma share price has climbed 8.8% higher today and provided an afternoon product update. Why is the MGC Pharma share price charging? MGC Pharma yesterday provided...

Summary Several ASX-listed companies have released their quarterly results in the last few days, attracting significant market attention. Genetic Signatures reported strong quarterly and YTD sales driven by the increasing demand for it...

Summary Medicinal cannabis player MGC Pharmaceuticals has a historic quarter with the ground-breaking achievement of listing on the LSE. Oncology company Race Oncology has an action-packed quarter with significant progress on the Three...

MGC Pharma became the first medicinal cannabis company to list on the London Stock Exchange, amid record sales of its phytomedicines.

Summary Drug discovery company developing new therapies, Dimerix, has enrolled multiple patients in REMAP-CAP study in Europe. In the ACE2 RAS study domain, subjects will be randomised to receive one RAS blockade strategy or control....

Summary Australian players MGC Pharmaceuticals and ArchTIS limited were under the spotlight following recent crucial developments. Biopharma player MGC Pharma announced the acquisition of MediCaNL that is likely to deliver cost savings...

ASX-listed MGC Pharmaceuticals has snapped up clinical and medical research company MediCaNL which will now conduct all clinical trials as an internal unit of the company. The acquisition is expected to produce significant cost savings and...

MGC Pharma to bring clinical trials research company MediCaNL’s services in-house Transaction is for $6m in MGC Pharma shares and will deliver significant cost savings and advantages ‘The acquisition of MediCaNL is a strategically importan...

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is soaring today after news the company will acquire clinical research company, MediCaNL Inc. MediCaNL will design, manage and run the biopharma company’s future clinical trials. The MGC P...

The acquisition leverages the medical research expertise in-house which will reduce preclinical lead times, provide the ability to better define clinical trial protocols and build stronger relationships with regulators moving forward.

Summary Health House International has signed a non-exclusive distribution agreement with Dragonfly Biosciences. The agreement with Dragonfly would strengthen Health House’s product portfolio within Australia. The distribution agreeme...

Source: photolona, Shutterstock Summary Australian Primary Hemp has signed another retail distribution agreement with Coles Group Limited. Cannabis player Little Green Pharma has entered into a non-exclusive distribution agreement wit...

MGC Pharma, which has three investigational medical products in three clinical trials, has reported a record quarter of sales and revenue.

The number of medical cannabis prescriptions issued under Australia’s special access scheme just keeps on growing. There were a record 9,959 SAS Category B marijuana prescriptions issued in March, two and a half times the number from a year...

ASX and LSE-listed MGC Pharmaceuticals has banked a record $880,000 in quarterly revenue from sales of its phytomedicine products after delivering the first major batch of its ArtemiC Rescue anti-inflammatory formulation to Swiss PharmaCan...

Source: DG PhotoStock, Shutterstock Summary ASX-cannabis player Bod Australia has obtained a binding purchase order (PO) for CBD products in the US. Another cannabis player, MGC Pharmaceuticals, has completed the delivery of the first...

Medicinal cannabis biotech company MGC Pharmaceuticals (ASX:MXC) has delivered the first batch of purchase orders for its ArtemiCTM Rescue from Swiss PharmaCan AG (SPC). The total order is worth $425,000 (around 275k euros) of wholesale rev...

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is off to the races today, up 13% at the time of writing. The bio-pharma company produces and develops cannabis-derived medicines. Let’s take a look at the ASX cannabis share’s latest prod...

Bio-pharma company, MGC Pharmaceuticals has received ethics committee approval from two Israeli hospitals for a Phase III clinical trial of its trademarked “CimetrA” anti-inflammatory treatment on a large group of moderately sick, hospitali...

Source: create jobs 51, Shutterstock Summary MGC Pharmaceuticals has received approval from the Ethics Committee for Phase 3 clinical trial of CimetrATM in COVID-19 patients. eHealth SaaS player Respiri Limited has obtained US FDA’s a...

MGC Pharmaceuticals (ASX: MXC) shares are on the rise today after the company advised two ethics committees have passed its product for phase III clinical trials on COVID-19 patients. At the time of writing, the MGC Pharmaceuticals share p...

Medicinal cannabis biotech company MGC Pharmaceuticals (ASX:MXC) can proceed to a Phase III clinical trial of its anti-inflammatory medicine for the treatment of COVID-19. Ethics committees at Nazareth Hospital and the Rambam Health Care Ca...

The North American cannabis market received a huge shakeup this week, after British American Tobacco (LON: BATS) announced that it would be purchasing a 19.9% stake in the Canadian cannabis producer, Organigram (TSE: OGI), for $175 million....

Pot legalisation is creeping across the US state by state, and a major market could be about to join their ranks. Reports out of New York indicate that lawmakers in the Empire State are close to signing a new bill legalising recreational ca...

Source: Stereo Lights, Shutterstock Summary The Australian cannabis industry is in an infant stage and can offer several opportunities to market participants with a keen interest in this space. Developer and supplier of cannabis produ...

Source: ITTIGallery ,Shutterstock Summary Metalstech’s share price has shot up by 45.8 per cent after the announcement of its commercialization strategy. Nanoveu released updates regarding its suite of antiviral protection technologie...

Bio-pharma group MGC Pharmaceuticals has received a much larger initial purchase order from European nutraceutical producer and distributor, Swiss PharmaCan for the ASX-listed outfit’s anti-inflammatory product, ArtemiC Rescue.

The MGC Pharmaceuticals Ltd [ASX:MXC] share price is up after its leading European distributor increased purchase order volume of MGC’s ArtemiC by 85%. The MGC share price jumped 7% in early trading... The post MGC Pharmaceuticals Shares A...

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is gaining today, up 2.5% in late morning trade. MGC Pharmaceuticals (MGC Pharma) is a biopharma company that produces and develops phytocannabinoid-derived medicines. This morning, it ann...

Source: metamorworks,Shutterstock Summary MGC Pharmaceuticals has received an increased purchase order of ArtemiCTM Rescue from Swiss PharmaCan AG. The total order value now holds above $425,000, which would be translated to an immedi...

"This further agreement will provide more people access to the natural therapeutic benefits of the supplement,” said managing director Roby Zomer

Milestones during the period included an acquisition, first product shipments, expansion of manufacturing facilities and continued clinical progress

Source: Shutterstock Summary Fast-paced economic recovery seems to be driving the popularity of penny stocks in February 2021.  The unemployment rate dropped by 0.2% during January 2021.  While Penny stocks offer significant growth p...

The MGC Pharmaceuticals Ltd (ASX: MXC) share price zoomed up more than 35% higher today off the back of a positive announcement released to the market yesterday.   In a strong finish at the close of trade today, the MCG Pharma share price...

The company is also carrying out clinical trials of ArtemiC into the treatment of COVID-19

The company has signed a minimum three-year exclusive worldwide supply and distribution agreement with Swiss PharmaCan for the distribution of ArtemiC™ Rescue as a food supplement.

Summary European based bio-pharma player MGC Pharmaceuticals has entered into an exclusive worldwide supply and distribution agreement for ArtemiCTM. MGC Pharma has the ample manufacturing capacity to produce commercial-scale batches o...

London's cannabis sector is finally budding two decades after GW Pharma blazed a trail, with debutants MGC Pharmaceuticals and Kanabo Group both warmly welcomed after listing this month

MGC Pharmaceuticals and Kanabo Group have both had a warm welcome after listing this month

London Stock Exchange-listed MGC Pharma expands brain cancer treatment research ‘Importantly, we are now moving forward with our next stage ... Read More The post MGC Pharmaceuticals launches new clinical study into brain cancer treatment a...

The MGC Pharmaceuticals Ltd (ASX: MXC) share price has been smoking the market on Wednesday. In afternoon trade the medicinal cannabis company’s shares are up 8% to 3.9 cents. This latest gain means the MGC Pharma share price is now up alm...

Summary The cash net profit after tax for Commonwealth Bank of Australia stood at A$3.89 billion for the six months to 31 December 2021, as against A$4.36 billion in the corresponding period last year.  The statutory net profit after t...

The medicinal cannabis developer was valued at £33.7mln on London debut

The medicinal cannabis developer was valued at £33.7mln on London debut

Summary Several ASX- listed companies are under the spotlight amid ongoing reporting season. The Commonwealth Bank of Australia (ASX:CBA) share price will be on watch this week as the market expects an increase in dividends. MGC Pharm...

Despite shying away from the limelight again recently, pot stocks continue to make ground. With several local players steadily advancing towards their goals. Today, that is exactly what MGC Pharmaceuticals Ltd [ASX:MXC] has done... The post...

Summary European biopharma company MGC Pharmaceuticals is on the verge of getting listed on the London Stock Exchange (LSE). The cannabis player has completed a placement for £6.5 million headed by top UK institutional funds. MGC Phar...

MGC Pharma will maintain a dual LSE and ASX listing to significantly broaden the company’s international profile and provide direct access to UK and European institutional and other investors.